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Abstract: Although there is increasing evidence that aberrant expression of those enzymes 
which control protein arginine methylation contribute to carcinogenesis, their de-regulation 
by oncogenic viruses in primary cells has yet to be reported. We first show that the protein 
arginine methyltransferases, CARM1, PRMT1 and PRMT5 are strongly expressed in 
Hodgkin Reed-Sternberg (HRS) cells, and up-regulated in Hodgkin's lymphoma (HL) cell 
lines. Given that Epstein-Barr virus (EBV) can be detected in approximately 50% of 
primary HL, we next examined how EBV infection of germinal centre (GC) B cells, the 
presumptive precursors of HRS cells, modulated the expression of these proteins. EBV 
infection of GC B cells was followed by the up-regulation of CARM1, PRMT1 and 
PRMT5, and by the down-regulation of the arginine deiminase, PADI4. Latent membrane 
protein 1 (LMP1), the major EBV transforming gene was shown to induce PRMT1 in GC 
B cells and in a stably transfected B cell line. The recent development of compounds which 
inhibit PRMT-mediated reactions provides a compelling case for continuing to dissect the 
contribution of virus induced changes in these proteins to lymphomagenesis.  
Keywords: protein arginine methyltransferases; Epstein-Barr virus; LMP1; Hodgkin’s 
lymphoma; PRMT1; epigenetics 
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1. Introduction 
Protein arginine methylation is a post-translational modification which involves the addition of a 
methyl group to one or two terminal nitrogen atoms on arginine residues. In mammals, there are  
nine protein arginine methyltransferases (PRMT1-3, CARM1, PRMT5-9,) which catalyse arginine 
methylation [1]. The peptidylarginine deiminases (PADI), a family of five Ca
2+
 dependent enzymes, 
effectively act as arginine demethylases by catalysing the conversion of an arginine residue to a 
citrulline residue [2,3]. In addition to being involved in a number of cellular processes, including DNA 
repair, RNA transcription, signal transduction and protein compartmentalization, arginine methylation 
is also important for the replication of viruses and the transcriptional activation and stabilisation of 
viral proteins [1]. PRMT1 regulates replication of herpes simplex virus; is required for the efficient 
production of adenovirus type-5; and modulates Kaposi sarcoma-associated herpesvirus gene 
expression during its life cycle [4–6]. PRMT1 and PRMT5 binding to the Epstein Barr virus (EBV) 
protein EBNA1 is important for the replication and mitotic segregation of viral genomes [7]. Arginine 
methylation of another EBV oncoprotein, EBNA2, is necessary for its efficient association with  
DNA bound transcription factors and with other viral promoters [8]. PRMT1. CARM1 enhances 
transcriptional activation of the HTLV-1 encoded oncoprotein, Tax, and PRMT6 increases the stability 
of the human immunodeficiency virus type 1 transactivator protein, Tat [9,10].  
While these examples illustrate how viruses can exploit the cell’s arginine methylation machinery, 
virus-induced de-regulation of the PRMT has been less extensively investigated. Hepatitis C virus and 
Human Papilloma Virus E6 protein have been shown to down-regulate arginine methyltransferase 
activity in transformed cells [11,12]. However, virus induced de-regulation of these proteins in primary 
cells has not been reported. Here, we investigate how EBV and its major transforming gene, encoding 
latent membrane protein 1 (LMP1) which can be detected in approximately 50% of cases of primary 
Hodgkin's lymphoma (HL), modulate the expression of proteins which regulate arginine methylation in 
germinal centre (GC) B cells, the presumptive progenitor cells of HL [13]. We focus on three PRMT 
(PRMT1, PRMT5, and CARM1) and one deiminase (PADI4) which were found to be differentially 
expressed on gene expression profiling of EBV infected GC B cells. PRMT1 contributes 85% of all 
cellular PRMT activity and co-activates with CARM1, NF-Kappa B dependent gene expression, a 
pathway which is constitutively activated in many lymphomas including HL [14–16]. PRMT5 has 
been shown to be over-expressed in BL cell lines; to suppress the retinoblastoma family of tumour 
suppressors in leukaemia and lymphoma cells; and to mediate CCND1-dependent neoplastic growth in 
a mouse lymphoma model [17,18]. Ectopic expression of the deaminase, PADI4, has been shown to 
inhibit the growth of transformed B cells [19]. 
2. Results and Discussion 
2.1. Protein Arginine Methyltransferases Are Differentially Expressed in Primary HL 
We have previously shown using gene expression profiling, up-regulation of PRMT1, PRMT5 and 
CARM1 in one or more HL cell lines [20,21]. We were able to confirm increased protein expression of 
these PRMT in HL cell lines (Figure 1). We also measured using immunohistochemistry, the 
expression of CARM1, PRMT1 and PRMT5 in 77 cases of primary HL (17 paediatric and 60 adult). 
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These proteins were found to be strongly expressed in HRS cells when compared with surrounding 
lymphocytes and with normal tonsillar tissue (Figure 2). Consistent with reports describing the 
distribution of CARM1 and PRMT1 expression in different cell types [1,22,23], there was evidence of 
both nuclear and cytoplasmic staining for CARM1 and PRMT1 in the majority of patients with HL 
(Table 1). For PRMT5, staining was predominantly cytoplasmic as has been described elsewhere [24,25] 
(Table 1). Although the intensity of staining did not vary significantly with histological subtype or age 
at diagnosis (Supplementary Tables 1 and 2), the proportion of cases with strong nuclear staining for 
PRMT1 was greater in those who tested positive for EBV (X
2
 3df = 11.0; p = 0.005); CARM1 or 
PRMT5 expression did not vary significantly with EBV status (Table 2).  
Figure 1. PRMT1, PRMT5 and CARM1 expression in five Hodgkin's lymphoma (HL) cell 
lines. Western blot showing PRMT expression in HL cell lines compared to GC B cells. 
MCM7 was used as a loading control. 
 
Figure 2. Expression of PRMT in primary HL: Hodgkin Reed-Sternberg (HRS) cells were 
strongly positive for PRMT1, PRMT5 and CARM1 when compared to surrounding 
lymphocytes and tonsillar tissue. 
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Table 1. Immunohistochemical staining of 77 cases of HL for PRMT1, PRMT5 and 
CARM1. Both nuclear and cytoplasmic PRMT expression was recorded as weak when 
staining of HRS cells was less than that observed in the surrounding lymphocytes; 
moderate when staining of HRS cells was as strong as that observed in the surrounding 
lymphocytes; and strong when staining of HRS cells was greater than that in the 
surrounding lymphocytes.  
Immunohistochemical staining of 77 cases of Hodgkin’s Lymphoma for PRMT1, CARM1 and PRMT5 
Gene  Intensity of Cytoplasmic Staining 
PRMT1 * 
intensity of 
nuclear staining 
 
strong moderate weak negative Total 
strong 22 (12) 10 (1) 3 8 43 
moderate 0 25 (11) 3 4 32 
weak 0 0 1 0 1 
negative 0 0 0 0 0 
CARM1 ** 
intensity of 
nuclear staining 
strong 26 6 0 0 32 
moderate 11 14 1 0 26 
weak 4 3 4 0 11 
negative 0 1 2 1 4 
PRMT5 * 
intensity of 
nuclear staining 
strong 4 [2] 0 0 0 4 
moderate 2 [2] 10 [5] 0 0 12 
weak 7 5 1 0 13 
negative 25 21 0 1 47 
* 1 and ** 4 cases were not evaluable. Numbers and parenthesis refer to those cases which cytoplasmic staining 
was occasional. Numbers in square brackets refer to those cases in which nuclear staining was occasional. 
Table 2. Influence of EBV status: comparison of immunohistochemical staining for 
PRMT1, CARM1 and PRMT5 in nodular sclerosis and mixed cellularity HL. Both nuclear 
and cytoplasmic PRMT expression was recorded as weak when staining of HRS cells was 
less than that observed in the surrounding lymphocytes; moderate when staining of HRS 
cells was as strong as that observed in the surrounding lymphocytes; and strong when 
staining of HRS cells was greater than that in the surrounding lymphocytes. 
Influence of EBV Status: Comparison of Immunohistochemical Staining for PRMT1, CARM1 and PRMT5 in 
EBV Positive (n = 27) and EBV Negative (n = 50) 
intensity of  
nuclear staining 
 
PRMT1 CARM1 PRMT5 
 
EBV 
negative 
EBV 
positive 
EBV 
negative 
EBV 
positive 
EBV 
negative 
EBV 
positive 
strong 21 22 24 9 3 2 
moderate 27 5 16 9 7 4 
weak 1 0 5 6 8 5 
negative 0 0 3 1 31 16 
 X2 3df = 11; p = 0.005 X
2 3df = 2.9; p = 0.41 X
2 3df = 0.1; p = 0.99 
intensity of 
cytoplasmic staining 
strong 12 10 26 16 25 13 
moderate 25 10 14 9 23 13 
weak 6 1 7 0 0 1 
negative 6 6 1 0 1 0 
 
X2 3df = 4.2; p = 0.24 X
2 3df = 4.4; p = 0.06 X
2 3df = 3.4; p = 0.3 
* 1 and ** 4 cases were not evaluable. Numbers and parenthesis refer to those cases which cytoplasmic staining 
was occasional. Numbers in square brackets refer to those cases in which nuclear staining was occasional. 
Pathogens 2012, 1 56 
 
 
2.2. EBV Infection Modulates the Expression of the Protein Arginine Methyltransferases  
As EBV is believed to contribute to the pathogenesis of HL, we next investigated whether this 
oncogenic virus modulates the expression of these proteins in germinal centre (GC) B cells, the 
presumptive progenitor cells of HL. We first examined the expression of these proteins in three LCL 
derived from GC B cells isolated from different donors. Compared with their expression in GC B cells, 
PRMT1, PRMT5 and CARM1 were up-regulated at the RNA (Figure 3A) and protein level  
(Figure 3B) in all three LCL. PADI4 was substantially decreased at the RNA level (Figure 3A), but its 
protein could not be examined because no western blotting antibody was available. Using RNA 
collected from earlier time-points we found that PRMT1 was up-regulated within 96 hours of EBV 
infection whilst up-regulation of PRMT5 and CARM1 was delayed for 7 days (Figure 4).  
Figure 3. (A and B) PRMT1, PRMT5, CARM1 and PADI4 expression in GC B cells and 
EBV infected GC B cells. (A) Q-RT PCR showing PRMT and PADI4 expression. Grey 
bars represent expression in GC B cells isolated from three different patients (1,2,3) and 
black bars that in each of the corresponding EBV infected GC B cells. The GC B cells with 
the highest expression of the gene in question served as the reference sample. Assays were 
carried out in triplicate and results are presented as 2
−∆∆CT
 values; (B) Western blot 
showing PRMT expression in GC B cells and in corresponding EBV infected GC B cells; 
MCM7 was used as a loading control. 
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Figure 4. Kinetics of PRMT1, PRMT5 and CARM1 expression in GC B cells and in 
LCLs. Q RT-PCR showing changes in PRMT expression in GC B cells infected with EBV 
compared to GC B cells. Assays were carried out in triplicate and results are presented as 
2
−∆∆CT
 values. Experiments were performed on the three LCLs and representative results 
for one LCL are shown.  
 
2.3. PRMT1 is Up-Regulated in B Cells by the EBV Oncogene, LMP1  
Given that we and others have shown that the major EBV transforming gene in HL, latent 
membrane protein 1 (LMP1), is usually first detected 72–96 hours following EBV infection [21], we 
next investigated whether this oncogene modulated the expression of PRMT1, PRMT5 and CARM1 in 
LMP1-transfected CD10
+ve
 GC B cells. Towards this end, GC B cells isolated from two tonsils 
removed from different patients were transfected with either an LMP1-expressing pSG5-LMP1 
expression vector or with a pSG5 vector control as previously described [21]. Q RT-PCR confirmed 
the up-regulation of PRMT1 in RNA isolated 24 hours following transfection with LMP1 from both 
preparations of GC B cells (Figure 5A). However, we found no evidence to suggest that LMP1 
regulates the expression of either PRMT5 or CARM1 in GC B cells. We confirmed LMP1-induced  
up-regulation of PRMT1 at the RNA and protein level in the EBV negative BL cell line DG75 using 
an inducible expression system in which removal of tetracycline is followed by induction of LMP1 
expression (Figure 5B and 5C) [26]. PRMT1 was also shown to be up-regulated at the protein level in 
naive B cells 7 days following EBV infection (Figure 5D). However, we found no evidence to suggest 
that LMP2A or EBNA1 modulates the expression of any of the enzymes under consideration in GC B 
cells (data not shown).  
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Figure 5. (A–D): LMP1 up-regulates PRMT1. (A) Q RT-PCR showing up-regulation of 
PRMT1 following transfection of GC B cells with LMP1. Assays were performed in 
triplicate and the results are presented as 2
−∆∆CT
 values compared to the vector control, 
pSG5; (B and C) LMP1-induced up-regulation of PRMT1 at the RNA and protein level 
using a tetracycline-inducible expression system. Tet + refers to the cells grown in the 
presence of tetracycline and Tet- to those grown without. Protein assays were performed in 
triplicate. MCM7 was used as a loading control; (D) Western blotting showing the increase 
in PRMT1 expression 7 days post infection of naive B cells with EBV. MCM7 was used as 
a loading control. 
 
3. Experimental Section  
3.1. Isolation and Infection of Tonsillar GC B Cells  
Tonsillar tissue was obtained from the Children’s Hospital Birmingham following informed consent 
(reference number for ethical approval 06/Q2702/50). Mononuclear cells were isolated by Ficoll-Isopaque 
centrifugation and CD10
+
 GC B cells by magnetic separation on LS columns (Miltenyi Biotec, 
Germany) using α-CD10-Phycoerythrin (PE) (eBioscience, UK) and α-PE microbeads (Miltenyi 
Biotec). Wild-type 2,089 EBV particles were produced from 293 cells carrying a recombinant B95.8 
EBV genome (kindly provided by Dr. Claire Shannon-Lowe) and virus copy number was measured 
using a BALF5 quantitative PCR (Q-PCR) assay. GC B cells (2 × 10
6
) were infected overnight on a 
fibroblast feeder layer with 2,089 EBV at a multiplicity of infection of 50. 
3.2. Maintenance of Cell Lines 
GC B cell derived LCLs were established and maintained for six weeks at 37 °C in RPMI 1,640 
medium (Sigma-Aldrich, Missouri USA) supplemented with 10% foetal calf serum (FCS) and 1% 
penicillin/streptomycin (Invitrogen, CA, USA) (20). LMP1 inducible DG75 cells were maintained  
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in RPMI 1640, 10% FCS, 1% penicillin/streptomycin, 1.5 mg/mL G418, 0.5 mg/mL hygromycin  
(Sigma-Aldrich) and 1 µg/mL tetracycline; whereas cells cultured with tetracycline did not express 
LMP1, those grown in the absence of tetracycline expressed this viral oncogene (26).  
3.3. Quantitative Reverse Transcriptase-Polymerase Chain Reaction 
Total RNA was extracted using RNeasy Mini kit (Qiagen, Germany). cDNA was generated using 
the Superscript III First-strand synthesis system (Invitrogen) with random primer (Promega, UK).  
Q-PCR assays were prepared in a final volume of 25 μL which contained 1 μL cDNA, TaqMan 
universal PCR mastermix (Applied Biosystems, CA, USA), B2M house-keeping assay (Applied 
Biosystems) and Taqman assay for the target genes, PRMT1 Hs01587651_g1, PRMT5 Hs01047356_m1, 
CARM1 Hs00406354_m1 and PADI4 Hs00202612_m1 (Applied Biosystems). Q-PCR assays were 
performed in triplicate using an ABI Prism 7,700 sequence detection system (Applied Biosystems). 
The 2
−ΔΔ
 CT method was used to quantify expression relative to the housekeeping control.  
3.4. Western Blotting 
Cells (1 × 10
7
) were lysed in 100 µL RadioImmuno Precipitation Assay (RIPA) buffer (50 mM 
Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate (SDS), 1 mM sodium vanadate and protease inhibitor cocktail (Promega)). Protein was 
denatured by heating to 90 °C in SDS buffer, run on a–polyacrylamide gel before being transferred to 
BioTrace NT membrane (VWR International, USA), and then incubated overnight with primary 
antibody diluted in 5% (w/v) milk. Antibodies used were: PRMT1 mouse monoclonal antibody  
(Sc-59648, Santa Cruz, California, USA) at 1:2,000 dilution; PRMT5 mouse monoclonal antibody  
(Ab-12191, Abcam, Cambridge, UK) at 1:2,000 dilution; CARM1 mouse monoclonal antibody 
(Ab50278, Abcam) at 1:1,000 dilution; LMP1 monoclonal antibody (Dako, Denmark) at 1:2,000 
dilution. MCM-7 (Sigma-Aldrich) at 1:2,000 dilution was used as a loading control. Following 
washing with TBS-T, blots were incubated for 1 hour with the appropriate HRP-conjugated secondary 
antibody (Dako, Denmark). Proteins were visualised using the enhanced chemiluminescence (ECL) 
technique (GE healthcare, UK). 
3.5. Immunohistochemistry 
Immunohistochemistry was performed on normal tonsillar tissue removed at the time of 
tonsillectomy, and on 60 adult and 17 paediatric HL biopsies. Sections of paraffin-embedded tissues 
were cut at 4 µm thickness and dried at 60 °C for 1 hour. Sections were de-waxed, rehydrated and 
endogenous peroxidise activity blocked in 0.3% H2O2 (Sigma-Aldrich) for 15 minutes. Non-specific 
binding was blocked using 5× casein solution (Vector Laboratories, UK). Sections were incubated with 
the following primary antibodies for 16 hours at 4 °C: PRMT1 (sc59648; Santa Cruz); CARM1 
(ab50278; Abcam) and PRMT5 (07-405; Upstate Millipore, CA, USA). Negative isotype controls 
were, mouse IgG1 (X0931; Alere, Chesire, UK), mouse IgG3 (MAB007; R & D Systems Europe Ltd, 
Abingdon, UK) and rabbit IgG (X0936; Alere), respectively. Dako Real Envision™ dual mouse/rabbit 
peroxide-conjugated was used as a secondary antibody. The staining was visualised with Dako Real 
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Envision™ DAB chromagen and solution (Dako). Sections were counter-stained with Mayer’s 
Haematoxylin (Leica Microsystems, Peterborough, UK). 
4. Conclusions  
We have shown for the first time that EBV modulates the expression of those proteins involved in 
the regulation of arginine methylation. EBV infection of GC B cells, the presumptive progenitors of 
the Reed Sternberg cells found in HL, was followed by the up-regulation of the protein arginine 
methyltransferases CARM1, PRMT1 and PRMT5, and by the down-regulation of the deiminase, 
PADI4. This PRMT expression pattern was recapitulated in primary HL, and is entirely consistent with 
the results of gene expression profiling reported for micro-dissected HRS cells [27].  
The up-regulation of PRMT1 within 96 hours of EBV infection is consistent with the time at which 
LMP1 can be first detected. However, up-regulation of PRMT5 and CARM1 was not seen until day 7, 
suggesting that their up-regulation is mediated either by other EBV genes or simply a consequence of 
proliferation. While we were also able to show that the proportion of cases with strong nuclear staining 
for PRMT1 was significantly greater in those who tested positive for EBV, it is important to note that 
PRMT1, PRMT5 and CARM1 were also over-expressed in EBV negative HL. Recently an inhibitor of 
arginine methyltransferases was shown to reduce Tax transactivation in HTLV-1 transformed cells 
while at the same reducing NF Kappa B activity [28]. As NF Kappa B is constitutively increased in 
both EBV positive and EBV negative HL, this would provide a common pathway explaining the  
up-regulation of PRMT1 in both virus positive and virus negative disease.  
Our observations offer some clues as to how EBV-induced changes in the expression of the PRMT 
might contribute to disturbances of B cell differentiation, and therefore to B cell lymphomagenesis. 
Signals processed through the B cell antigen receptor control both proliferation and differentiation. 
PRMT1 induced methylation of a conserved arginine residue in the CD79A subunit of the BCR has 
been shown to promote signals leading to B cell differentiation, an effect mediated in part by the 
modulation of calcium signalling [29]. We have shown that PRMT1 is up-regulated in GC B cells by 
LMP1 which has also been shown to increase the storage of Ca
2+
 in the endoplasmic reticulum in B 
cells [30]. Given that we have shown LMP1 can drive cells towards a post GC stage while at the same 
time hijacking the B cell transcriptional programme and subverting normal B cell differentiation [20], 
it will be important to investigate further the contribution of virus-induced de-regulation of PRMT1 to 
this process.  
More than thirty years ago inhibition of PRMT1 was first shown to inhibit Rous sarcoma virus 
induced chick embryo fibroblast transformation [31]. Small molecule inhibitors specific for the PRMT 
continue to be developed and while most of this activity has focused on inhibition of enzymatic 
activity, more recently compounds have been discovered which bind to PRMT substrates [32,33]. This 
continuing intensive effort provides a compelling reason for endeavouring to dissect the contribution to 
transformation of virus induced changes in the activity of these proteins. 
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Supplemental Table 1. Influence of histological type: comparison of immunohistochemical 
staining for PRMT1, CARM1 and PRMT5 in nodular sclerosis and mixed cellularity HL. 
Both nuclear and cytoplasmic PRMT expression was recorded as weak when staining of 
HRS cells was less than that observed in the surrounding lymphocytes; moderate when 
staining of HRS cells was as strong as that observed in the surrounding lymphocytes; and 
strong when staining of HRS cells was greater than that in the surrounding lymphocytes. 
Influence of Histological Type: Comparison of Immunohistochemical Staining for PRMT1, CARM1 and 
PRMT5 in Nodular Sclerosis (NS, n = 40) and Mixed Cellularity (MC, n = 37) 
intensity of  
nuclear staining 
 
PRMT1 CARM1 PRMT5 
 
NS MC NS MC NS MC 
strong 21 22 15 17 2 2 
moderate 17 15 13 13 7 5 
weak 1 0 9 2 7 6 
negative 1 0 1 3 23 24 
 X2 3df = 3.0; p = 0.39 X
2
 3df = 5.5; p = 0.14 X
2
 3df = 0.4; p = 0.94 
intensity of 
cytoplasmic staining 
strong 11 11 22 19 18 20 
moderate 17 18 12 12 19 17 
weak 5 2 4 3 1 0 
negative 6 6 0 1 1 0 
 X2 3df = 1.3; p = 0.73 X
2
 3df = 1.8; p = 0.62 X
2
 3df = 3.1; p = 0.37 
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Supplemental Table 2. Influence of age of diagnosis: comparison of immunohistochemical 
staining for PRMT1, CARM1 and PRMT5 in nodular sclerosis and mixed cellularity HL. 
Both nuclear and cytoplasmic PRMT expression was recorded as weak when staining of 
HRS cells was less than that observed in the surrounding lymphocytes; moderate when 
staining of HRS cells was as strong as that observed in the surrounding lymphocytes; and 
strong when staining of HRS cells was greater than that in the surrounding lymphocytes. 
Influence of Age of Diagnosis in: Comparison of Immunohistochemical Staining for PRMT1, CARM1 and 
PRMT5 in Paediatric (n = 17) and Adult (n = 60) Cases 
intensity of  
nuclear staining 
 
PRMT1 CARM1 PRMT5 
 
adult paediatric adult paediatric adult paediatric 
3 43 8 32 4 4 2 
2 32 8 26 9 12 5 
1 1 0 11 4 13 2 
0 1 0 4 0 47 7 
 X2 3df = 1.1; p = 0.79 X
2 3df = 4.0; p = 0.26 X
2 3df = 3.7; p = 0.3 
intensity of 
cytoplasmic staining 
3 22 4 41 9 38 7 
2 35 7 24 8 36 9 
1 7 0 7 0 1 0 
0 12 5 1 0 1 0 
 X2 3df = 4.5; p = 0.21 X
2 3df = 4.2; p = 0.24 X
2 3df = 1.1; p = 0.78 
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